ASCO: Kite's CAR T-Cell therapy Tecartus shows strong overall survival rates

6 June 2022
asco-big

Kite, a subsidiary of US biotech major Gilead Sciences (Nasdaq: GILD), over the weekend announced longer-term follow-up results from two pivotal studies of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).

The three-year follow-up of ZUMA-2, a Phase II global, multicenter study evaluating the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), and two-year follow-up of ZUMA-3, a global, multi-centre, single-arm, open-label Phase I/II study evaluating brexucabtagene autoleucel in adult patients (≥18 years old) with  R/R B-cell acute lymphoblastic leukemia (B-ALL) were both presented Sunday during a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Three-year follow-up data from ZUMA-2 were also simultaneously published in ASCO’s  Journal of Clinical Oncology.

“We are very encouraged by the totality of these data, which suggest a significant and sustained response with brexucabtagene autoleucel for people living with difficult-to-treat blood cancers like MCL and B-ALL,” said Dr Frank Neumann, senior vice president and global head of clinical development, at Kite. “These longer-term results add to the growing maturity of data on Kite’s CAR T-cell therapies,” he noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology